However, although there may be particular benefit in diabetic neuropathy, the preclinical data demonstrate the role of HCN channels and analgesic effect of ivabradine across neuropathic aetiologies, including traumatic nerve lesions and chemotherapy-induced neuropathy. Here, MALAT1 is linked to diabetic neuropathy.